

Latin America Chlorpheniramine Maleate Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$3999.00
- Five User License \$5299.00
- Corporate License \$6299.00

Report description:

Latin America Chlorpheniramine Maleate Market Report and Forecast 2024-2032

Latin America Chlorpheniramine Maleate Market Size

The global chlorpheniramine maleate market was valued at USD 514.9 million in 2023, with Latin America holding a significant market share. The market is driven by the rising prevalence of allergic conditions. It is expected to grow at a CAGR of 5.7% during the forecast period of 2024-2032, with the values likely to attain USD 848.1 million by 2032.

Latin America Chlorpheniramine Maleate Market Outlook

-[Recent data reveals that allergic rhinitis is one the most prevalent chronic diseases in the world, affecting 10-40% of the world's population. Out of this, Latin America covers a significant population segment. This high prevalence of allergic conditions directly impacts the market demand for effective antihistamines such as chlorpheniramine maleate.
-[One of the major Latin America chlorpheniramine maleate market trends is the rise in self-medication practices, particularly with over-the-counter (OTC) medicinal products such as chlorpheniramine maleate. In Brazil, self-medication prevalence rates are reported to range from 16.1% to 35.0%, with OTC drugs representing over 25% of the volume of marketed medicines.
-[In Brazil, around 10.9% of the total population is represented by people aged 65 or older. The rising aging population which is more prone to developing an allergic condition is poised to bolster the market share for antihistamine drugs. Latin America Chlorpheniramine Maleate Market Analysis

Chlorpheniramine maleate is the first-generation class of antihistamines primarily used to relieve symptoms associated with allergies and the common cold. It is available in the form of tablets, syrups, or even extended-release capsules. The medication works by blocking histamine, a substance in the body that causes symptoms of allergies, such as a runny nose or sneezing. The heightened awareness about allergy management, due to public health campaigns and improved healthcare services, is prompting people to seek treatment for allergy symptoms, thereby driving the Latin America chlorpheniramine maleate market growth.

The market is influenced by the increased prevalence of allergic conditions such as allergic rhinitis or seasonal allergies. Recent data reveals that allergic rhinitis is one the most prevalent chronic diseases in the world, affecting more than 400 million people and observed in 10-40% of the world's population. Latin America also experiences a high burden of this allergic condition , significantly impacting the quality of life and impairing development in children. The high prevalence of allergic rhinitis fuels the demand for effective and affordable antihistamines to manage the symptoms which is likely to augment the Latin America chlorpheniramine maleate market demand.

One of the major market trends is the increase in self-medication practices particularly with non-prescription or over-the-counter medicinal products including chlorpheniramine maleate medication. In Brazil, the prevalence rates of self-medication are reported to range from 16.1% to 35.0%. Moreover, the demand for over-the-counter drugs is increasing in the region, representing over 25% of the volume of marketed medicines. Since chlorpheniramine maleate is widely available as an over the counter and low-cost generic, the market share for the medication is expected to increase with the growing preference for self-care services and affordable treatment options.

The Latin America chlorpheniramine maleate market share is also influenced by the rising aging population which is more prone to developing an allergic condition. In Brazil, around 10.9% of the total population is represented by people aged 65 or older. The increase in the number of people in this age group is poised to bolster the demand for antihistamine drugs. Further, the rapid expansion of pharmaceutical distribution channels, including online pharmacies, is facilitating easier access to chlorpheniramine maleate products, which is anticipated to boost market growth in the forecast period.

Latin America Chlorpheniramine Maleate Market Segmentation??

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Dosage Form ?[]Tablets ?[]Syrup ?[]Eye Drops ?[]Others

Market Breakup by Application ?[]Allergy ?[]Hay Fever (Allergic Rhinitis) ?[]Common Cold ?[]Watery Eyes ?[]Itchy Throat/Skin ?[]Anaphylactic Shock ?[]Urticaria

Market Breakup by Distribution Channel ? Hospital Pharmacies ? Retail Pharmacies ? Online Pharmacies ? Others

Market Breakup by Country ?[]Brazil ?[]Argentina ?[]Mexico ?[]Others

Latin America Chlorpheniramine Maleate Market: Competitor Landscape

The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- -[Bayer AG
- -∏Novartis AG
- -∏Sanofi
- -]]ohnson & Johnson
- -[]Pfizer
- Boehringer Ingelheim
- -[]GlaxoSmithKline
- -[]Merck
- -[]Roche
- Teva Pharmaceutical Industries Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

-[]What is the Latin America chlorpheniramine maleate market forecast outlook for 2024-2032? The Latin America chlorpheniramine maleate market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 848.1 million by 2032.

-[]What are the major factors aiding the Latin America chlorpheniramine maleate market demand? The rising prevalence of allergic conditions along with awareness to manage such conditions effectively is fuelling the demand for the market.

- What are the major Latin America chlorpheniramine maleate market trends?

One of the significant trends in the market is the rise in self-medication practices, particularly with over the counter (OTC) medicinal products such as chlorpheniramine maleate. In Brazil, the self-medication prevalence rate is reported to range from 16.1% to 35.0%, with OTC drugs representing over 25% of the volume of marketed medicines.

-[]What is the market segmentation based on the dosage form?

Based on the dosage form, the market is segmented into tablets, syrup, and eye drops, among others.

-[]What are the major distribution channels of the market?

Distribution channels of the market are hospital pharmacies, retail pharmacies, and online pharmacies.

- What are the applications of chlorpheniramine maleate?

Major applications areas of include allergy, hay fever (allergic rhinitis), common cold, watery eyes, itchy throat/skin, anaphylactic shock, and urticaria.

- What is the market segmentation by countries?

The market segmentation by countries includes Brazil, Argentina, and Mexico, among others.

-[]Who are the key players involved in the Latin America chlorpheniramine maleate market?

The key players in the market are Bayer AG, Novartis AG, Sanofi, Johnson & Johnson, Pfizer, Boehringer Ingelheim,

GlaxoSmithKline, Merck, Roche, and Teva Pharmaceutical Industries Ltd.

Meta description

The Latin America chlorpheniramine maleate market is poised for growth, driven by the expansion of the global market, which

was valued at USD 514.9 billion in 2023 and is projected to grow at a CAGR of 5.7% during the forecast period of 2024-2032.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Latin America Chlorpheniramine Maleate Market Overview
 - 3.1 Latin America Chlorpheniramine Maleate Market Historical Value (2017-2023)
 - 3.2 Latin America Chlorpheniramine Maleate Market Forecast Value (2024-2032)
- 4 Latin America Chlorpheniramine Maleate Market Landscape*
 - 4.1 Latin America Chlorpheniramine Maleate: Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Latin America Chlorpheniramine Maleate: Product Landscape
 - 4.2.1 Analysis by Dosage Form
 - 4.2.2 Analysis by Application
- 5 Latin America Chlorpheniramine Maleate Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 Porter's Five Forces Model
 - 5.3.1 Bargaining Power of Suppliers
 - 5.3.2 Bargaining Power of Buyers
 - 5.3.3 Threat of New Entrants
 - 5.3.4 Threat of Substitutes
 - 5.3.5 Degree of Rivalry
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Latin America Chlorpheniramine Maleate Market Segmentation (2017-2032)
 - 6.1 Latin America Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
 - 6.1.1 Market Overview
 - 6.1.2 Tablets
 - 6.1.3 Syrup
 - 6.1.4 Eye Drops
 - 6.1.5 Others
 - 6.2 Latin America Chlorpheniramine Maleate Market (2017-2032) by Application
 - 6.2.1 Market Overview
 - 6.2.2 Allergy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

- 6.2.3 Hay Fever (Allergic Rhinitis)
- 6.2.4 Common Cold
- 6.2.5 Watery Eyes
- 6.2.6 Itchy Throat/Skin
- 6.2.7 Anaphylactic Shock
- 6.2.8 Urticaria
- 6.3 Latin America Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
 - 6.3.1 Market Overview
 - 6.3.2 Hospital Pharmacies
 - 6.3.3 Retail Pharmacies
 - 6.3.4 Online Pharmacies
- 6.4 Latin America Chlorpheniramine Maleate Market (2017-2032) by Country
 - 6.4.1 Market Overview
 - 6.4.2 Brazil
 - 6.4.3 Argentina
 - 6.4.4 Mexico
 - 6.4.5 Others
- 7 Brazil Chlorpheniramine Maleate Market (2017-2032)
 - 7.1 Brazil Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
 - 7.1.1 Market Overview
 - 7.1.2 Tablets
 - 7.1.3 Syrup
 - 7.1.4 Eye Drops
 - 7.1.5 Others
 - 7.2 Brazil Chlorpheniramine Maleate Market (2017-2032) by Application
 - 7.2.1 Market Overview
 - 7.2.2 Allergy
 - 7.2.3 Hay Fever (Allergic Rhinitis)
 - 7.2.4 Common Cold
 - 7.2.5 Watery Eyes
 - 7.2.6 Itchy Throat/Skin
 - 7.2.7 Anaphylactic Shock
 - 7.2.8 Urticaria
 - 7.3 Brazil Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
 - 7.3.1 Market Overview
 - 7.3.2 Hospital Pharmacies
 - 7.3.3 Retail Pharmacies
 - 7.3.4 Online Pharmacies
- 8 Argentina Chlorpheniramine Maleate Market (2017-2032)
 - 8.1 Argentina Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
 - 8.1.1 Market Overview
 - 8.1.2 Tablets
 - 8.1.3 Syrup
 - 8.1.4 Eye Drops
 - 8.1.5 Others
 - 8.2 Argentina Chlorpheniramine Maleate Market (2017-2032) by Application
 - 8.2.1 Market Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

- 8.2.2 Allergy
- 8.2.3 Hay Fever (Allergic Rhinitis)
- 8.2.4 Common Cold
- 8.2.5 Watery Eyes
- 8.2.6 Itchy Throat/Skin
- 8.2.7 Anaphylactic Shock
- 8.2.8 Urticaria
- 8.3 Argentina Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
 - 8.3.1 Market Overview
 - 8.3.2 Hospital Pharmacies
 - 8.3.3 Retail Pharmacies
 - 8.3.4 Online Pharmacies
- 9 Mexico Chlorpheniramine Maleate Market (2017-2032)
 - 9.1 Mexico Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
 - 9.1.1 Market Overview
 - 9.1.2 Tablets
 - 9.1.3 Syrup
 - 9.1.4 Eye Drops
 - 9.1.5 Others
 - 9.2 Mexico Chlorpheniramine Maleate Market (2017-2032) by Application
 - 9.2.1 Market Overview
 - 9.2.2 Allergy
 - 9.2.3 Hay Fever (Allergic Rhinitis)
 - 9.2.4 Common Cold
 - 9.2.5 Watery Eyes
 - 9.2.6 Itchy Throat/Skin
 - 9.2.7 Anaphylactic Shock
 - 9.2.8 Urticaria
 - 9.3 Mexico Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
 - 9.3.1 Market Overview
 - 9.3.2 Hospital Pharmacies
 - 9.3.3 Retail Pharmacies
 - 9.3.4 Online Pharmacies
- 10 Regulatory Framework
- 11 Funding and Investment Analysis
 - 11.1 Analysis by Funding Instances
 - 11.2 Analysis by Type of Funding
 - 11.3 Analysis by Funding Amount
 - 11.4 Analysis by Leading Players
 - 11.5 Analysis by Leading Investors
 - 11.6 Analysis by Geography
- 12 Partnership and Collaborations Analysis
 - 12.1 Analysis by Partnership Instances
 - 12.2 Analysis by Type of Partnership
 - 12.3 Analysis by Leading Players
 - 12.4 Analysis by Geography
- 13 Supplier Landscape

- 13.1 Market Share by Top 5 Companies
- 13.2 Bayer AG
 - 13.2.1 Financial Analysis
 - 13.2.2 Product Portfolio
 - 13.2.3 Demographic Reach and Achievements
 - 13.2.4 Mergers and Acquisitions
 - 13.2.5 Certifications
- 13.3 Novartis AG
 - 13.3.1 Financial Analysis
 - 13.3.2 Product Portfolio
 - 13.3.3 Demographic Reach and Achievements
 - 13.3.4 Mergers and Acquisitions
 - 13.3.5 Certifications
- 13.4 Sanofi
 - 13.4.1 Financial Analysis
 - 13.4.2 Product Portfolio
 - 13.4.3 Demographic Reach and Achievements
 - 13.4.4 Mergers and Acquisitions
 - 13.4.5 Certifications
- 13.5 Johnson & Johnson
 - 13.5.1 Financial Analysis
 - 13.5.2 Product Portfolio
 - 13.5.3 Demographic Reach and Achievements
 - 13.5.4 Mergers and Acquisitions
 - 13.5.5 Certifications
- 13.6 Pfizer
 - 13.6.1 Financial Analysis
 - 13.6.2 Product Portfolio
 - 13.6.3 Demographic Reach and Achievements
 - 13.6.4 Mergers and Acquisitions
 - 13.6.5 Certifications
- 13.7 Boehringer Ingelheim
 - 13.7.1 Financial Analysis
 - 13.7.2 Product Portfolio
 - 13.7.3 Demographic Reach and Achievements
 - 13.7.4 Mergers and Acquisitions
 - 13.7.5 Certifications
- 13.8 GlaxoSmithKline
 - 13.8.1 Financial Analysis
 - 13.8.2 Product Portfolio
 - 13.8.3 Demographic Reach and Achievements
 - 13.8.4 Mergers and Acquisitions
 - 13.8.5 Certifications
- 13.9 Merck
 - 13.9.1 Financial Analysis
 - 13.9.2 Product Portfolio
 - 13.9.3 Demographic Reach and Achievements

- 13.9.4 Mergers and Acquisitions
- 13.9.5 Certifications

13.10 Roche

- 13.10.1 Financial Analysis
- 13.10.2 Product Portfolio
- 13.10.3 Demographic
- 13.10.4 Mergers and Acquisitions
- 13.10.5 Certifications
- 13.11 Teva Pharmaceutical Industries Ltd.
 - 13.11.1 Financial Analysis
 - 13.11.2 Product Portfolio
 - 13.11.3 Demographic Reach and Achievements
 - 13.11.4 Mergers and Acquisitions
 - 13.11.5 Certifications
- 14 Latin America Chlorpheniramine Maleate Market Distribution Model (Additional Insight)
 - 14.1 Overview
 - 14.2 Potential Distributors
 - 14.3 Key Parameters for Distribution Partner Assessment
- 15 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 16 Company Competitiveness Analysis (Additional Insight)
 - 16.1 Very Small Companies
 - 16.2 Small Companies
 - 16.3 Mid-Sized Companies
 - 16.4 Large Companies
 - 16.5 Very Large Companies
- 17 Payment Methods (Additional Insight)
 - 17.1 Government Funded
 - 17.2 Private Insurance
 - 17.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.



Latin America Chlorpheniramine Maleate Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License		Price
	Single User License		\$3999.00
	Five User License		\$5299.00
	Corporate License		\$6299.00
		VAT	
		Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		
Company Name*	EU Vat / Tax ID / NIP number*	
Address*	City*	
Zip Code*	Country*	
	Date	2025-05-09
	Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com